Institut Rosell Expands Into Chile

MONTREALInstitut Rosell-Lallemand announced a probiotic preparation based on its proprietary strain, Lactobacillus plantarum 299v, which has been studied for the treatment of irritable bowel syndrome (IBS), was launched by Merck Chile as Bion Transit. More launches are expected in the South American market into 2008.

The licensing agreement signed with Merck Chile for Lp299v probiotic follows on the heels of the successful launch of Bion Transit by Merck Médication Familiale in France two years ago, said Sylvie Morin, sales and marketing director for the Americas, Institut Rosell (Lallemand.com). Bion Transit has become the leading probiotic targeting bloating and gas reduction in the French market, and we are confident that our Lp299v probiotic is a good candidate to penetrate the South American market as it constitutes a natural and clinically proven solution in supporting IBS sufferers.